16.08 USD
-0.45 (-2.72%)
16.11 USD
+0.03 (+0.19%)
SGRY gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 100 industry peers in the Health Care Providers & Services industry. SGRY has a medium profitability rating, but doesn't score so well on its financial health evaluation. SGRY has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year SGRY was profitable.
In the past year SGRY had a positive cash flow from operations.
In the past 5 years SGRY always reported negative net income.
In the past 5 years SGRY always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of -2.17%, SGRY is in line with its industry, outperforming 42.00% of the companies in the same industry.
SGRY has a Return On Equity of -9.97%. This is comparable to the rest of the industry: SGRY outperforms 42.00% of its industry peers.
SGRY's Return On Invested Capital of 5.63% is in line compared to the rest of the industry. SGRY outperforms 59.00% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for SGRY is below the industry average of 9.44%.
The 3 year average ROIC (5.03%) for SGRY is below the current ROIC(5.63%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.17% | ||
| ROE | -9.97% | ||
| ROIC | 5.63% |
ROA(3y)-1.04%
ROA(5y)-1.46%
ROE(3y)-4.24%
ROE(5y)-9.69%
ROIC(3y)5.03%
ROIC(5y)4.49%
1.3 Margins
SGRY has a better Operating Margin (15.96%) than 92.00% of its industry peers.
SGRY's Operating Margin has been stable in the last couple of years.
Looking at the Gross Margin, with a value of 26.57%, SGRY is in line with its industry, outperforming 55.00% of the companies in the same industry.
SGRY's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 15.96% | ||
| PM (TTM) | N/A | ||
| GM | 26.57% |
OM growth 3Y3.69%
OM growth 5Y1.42%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.83%
GM growth 5Y-0.73%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), SGRY is destroying value.
The number of shares outstanding for SGRY remains at a similar level compared to 1 year ago.
The number of shares outstanding for SGRY has been increased compared to 5 years ago.
The debt/assets ratio for SGRY is higher compared to a year ago.
2.2 Solvency
SGRY has an Altman-Z score of 0.77. This is a bad value and indicates that SGRY is not financially healthy and even has some risk of bankruptcy.
SGRY's Altman-Z score of 0.77 is on the low side compared to the rest of the industry. SGRY is outperformed by 76.00% of its industry peers.
The Debt to FCF ratio of SGRY is 18.37, which is on the high side as it means it would take SGRY, 18.37 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 18.37, SGRY is in line with its industry, outperforming 41.00% of the companies in the same industry.
A Debt/Equity ratio of 2.00 is on the high side and indicates that SGRY has dependencies on debt financing.
SGRY has a Debt to Equity ratio of 2.00. This is in the lower half of the industry: SGRY underperforms 73.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2 | ||
| Debt/FCF | 18.37 | ||
| Altman-Z | 0.77 |
ROIC/WACC0.64
WACC8.74%
2.3 Liquidity
A Current Ratio of 1.88 indicates that SGRY should not have too much problems paying its short term obligations.
SGRY has a better Current ratio (1.88) than 77.00% of its industry peers.
A Quick Ratio of 1.72 indicates that SGRY should not have too much problems paying its short term obligations.
SGRY has a better Quick ratio (1.72) than 72.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.88 | ||
| Quick Ratio | 1.72 |
3. Growth
3.1 Past
SGRY shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -17.02%.
SGRY shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.16%.
SGRY shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.20% yearly.
EPS 1Y (TTM)-17.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-31.58%
Revenue 1Y (TTM)10.16%
Revenue growth 3Y11.86%
Revenue growth 5Y11.2%
Sales Q2Q%6.63%
3.2 Future
Based on estimates for the next years, SGRY will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.89% on average per year.
SGRY is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.88% yearly.
EPS Next Y-29.92%
EPS Next 2Y-10.69%
EPS Next 3Y0.93%
EPS Next 5Y12.89%
Revenue Next Year6.88%
Revenue Next 2Y7.52%
Revenue Next 3Y7.62%
Revenue Next 5Y7.88%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 20.62, SGRY is valued on the expensive side.
70.00% of the companies in the same industry are more expensive than SGRY, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 26.76. SGRY is valued slightly cheaper when compared to this.
With a Price/Forward Earnings ratio of 21.45, SGRY is valued on the expensive side.
SGRY's Price/Forward Earnings is on the same level as the industry average.
SGRY is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 23.96, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.62 | ||
| Fwd PE | 21.45 |
4.2 Price Multiples
SGRY's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. SGRY is cheaper than 78.00% of the companies in the same industry.
84.00% of the companies in the same industry are more expensive than SGRY, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.72 | ||
| EV/EBITDA | 8.36 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.69%
EPS Next 3Y0.93%
5. Dividend
5.1 Amount
SGRY does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
16.08
-0.45 (-2.72%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners80.74%
Inst Owner Change5.61%
Ins Owners1.11%
Ins Owner Change-0.09%
Market Cap2.08B
Revenue(TTM)3.29B
Net Income(TTM)-172.50M
Analysts81.11
Price Target26.52 (64.93%)
Short Float %18.33%
Short Ratio8.22
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.56%
Min EPS beat(2)-23.03%
Max EPS beat(2)24.15%
EPS beat(4)2
Avg EPS beat(4)-2.06%
Min EPS beat(4)-24.34%
Max EPS beat(4)24.15%
EPS beat(8)5
Avg EPS beat(8)2.45%
EPS beat(12)9
Avg EPS beat(12)185.54%
EPS beat(16)10
Avg EPS beat(16)107.47%
Revenue beat(2)0
Avg Revenue beat(2)-1.38%
Min Revenue beat(2)-1.9%
Max Revenue beat(2)-0.85%
Revenue beat(4)1
Avg Revenue beat(4)-0.63%
Min Revenue beat(4)-2.1%
Max Revenue beat(4)2.34%
Revenue beat(8)3
Avg Revenue beat(8)-0.61%
Revenue beat(12)4
Avg Revenue beat(12)-0.71%
Revenue beat(16)5
Avg Revenue beat(16)-1.03%
PT rev (1m)-16.67%
PT rev (3m)-17.1%
EPS NQ rev (1m)-35.27%
EPS NQ rev (3m)-34.03%
EPS NY rev (1m)-24.86%
EPS NY rev (3m)-23.71%
Revenue NQ rev (1m)-6.83%
Revenue NQ rev (3m)-6.71%
Revenue NY rev (1m)-1.84%
Revenue NY rev (3m)-1.96%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.62 | ||
| Fwd PE | 21.45 | ||
| P/S | 0.63 | ||
| P/FCF | 10.72 | ||
| P/OCF | 7.38 | ||
| P/B | 1.2 | ||
| P/tB | N/A | ||
| EV/EBITDA | 8.36 |
EPS(TTM)0.78
EY4.85%
EPS(NY)0.75
Fwd EY4.66%
FCF(TTM)1.5
FCFY9.33%
OCF(TTM)2.18
OCFY13.56%
SpS25.43
BVpS13.38
TBVpS-26.33
PEG (NY)N/A
PEG (5Y)N/A
Graham Number15.32
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.17% | ||
| ROE | -9.97% | ||
| ROCE | 7.13% | ||
| ROIC | 5.63% | ||
| ROICexc | 5.63% | ||
| ROICexgc | 18.62% | ||
| OM | 15.96% | ||
| PM (TTM) | N/A | ||
| GM | 26.57% | ||
| FCFM | 5.9% |
ROA(3y)-1.04%
ROA(5y)-1.46%
ROE(3y)-4.24%
ROE(5y)-9.69%
ROIC(3y)5.03%
ROIC(5y)4.49%
ROICexc(3y)5.23%
ROICexc(5y)4.72%
ROICexgc(3y)18.5%
ROICexgc(5y)17.9%
ROCE(3y)6.37%
ROCE(5y)5.69%
ROICexgc growth 3Y0.79%
ROICexgc growth 5Y0.89%
ROICexc growth 3Y5%
ROICexc growth 5Y3.38%
OM growth 3Y3.69%
OM growth 5Y1.42%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.83%
GM growth 5Y-0.73%
F-Score4
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2 | ||
| Debt/FCF | 18.37 | ||
| Debt/EBITDA | 5.13 | ||
| Cap/Depr | 58.67% | ||
| Cap/Sales | 2.68% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 41.8% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.88 | ||
| Quick Ratio | 1.72 | ||
| Altman-Z | 0.77 |
F-Score4
WACC8.74%
ROIC/WACC0.64
Cap/Depr(3y)68.15%
Cap/Depr(5y)61.6%
Cap/Sales(3y)3.1%
Cap/Sales(5y)2.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-17.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-31.58%
EPS Next Y-29.92%
EPS Next 2Y-10.69%
EPS Next 3Y0.93%
EPS Next 5Y12.89%
Revenue 1Y (TTM)10.16%
Revenue growth 3Y11.86%
Revenue growth 5Y11.2%
Sales Q2Q%6.63%
Revenue Next Year6.88%
Revenue Next 2Y7.52%
Revenue Next 3Y7.62%
Revenue Next 5Y7.88%
EBIT growth 1Y17.2%
EBIT growth 3Y15.99%
EBIT growth 5Y12.78%
EBIT Next Year41.53%
EBIT Next 3Y20.05%
EBIT Next 5YN/A
FCF growth 1Y32.24%
FCF growth 3Y92.37%
FCF growth 5Y30.31%
OCF growth 1Y18.29%
OCF growth 3Y51.02%
OCF growth 5Y18.3%
SURGERY PARTNERS INC / SGRY FAQ
Can you provide the ChartMill fundamental rating for SURGERY PARTNERS INC?
ChartMill assigns a fundamental rating of 3 / 10 to SGRY.
Can you provide the valuation status for SURGERY PARTNERS INC?
ChartMill assigns a valuation rating of 4 / 10 to SURGERY PARTNERS INC (SGRY). This can be considered as Fairly Valued.
How profitable is SURGERY PARTNERS INC (SGRY) stock?
SURGERY PARTNERS INC (SGRY) has a profitability rating of 4 / 10.
Can you provide the PE and PB ratios for SGRY stock?
The Price/Earnings (PE) ratio for SURGERY PARTNERS INC (SGRY) is 20.62 and the Price/Book (PB) ratio is 1.2.
Is the dividend of SURGERY PARTNERS INC sustainable?
The dividend rating of SURGERY PARTNERS INC (SGRY) is 0 / 10 and the dividend payout ratio is 0%.